Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Linli Yao

Matched on OpenAlex author ID A5100517337. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 11

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.7150/ijbs.125552↗
  3. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Co-author DOI 10.1002/cac2.12637↗
  4. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Co-author DOI 10.1002/ctm2.70191↗
  5. ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Co-author DOI 10.1016/j.tranon.2024.102261↗
  6. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  7. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 … Last author DOI 10.1007/s13402-023-00791-z↗
  8. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  9. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  10. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  11. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. Co-author DOI 10.1155/2021/6694392↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Zhang · 8 shared papers, 2021–2026 · strength 1.26
  2. Shu‐Heng Jiang · 7 shared papers, 2021–2026 · strength 1.20
  3. Li-Peng Hu · 7 shared papers, 2021–2026 · strength 1.02
  4. Zhigang Zhang · 6 shared papers, 2021–2025 · strength 0.86
  5. Zong‐Hao Duan · 4 shared papers, 2023–2026 · strength 0.80
  6. Xiaomei Yang · 4 shared papers, 2022–2026 · strength 0.73
  7. Dejun Liu · 4 shared papers, 2022–2026 · strength 0.70
  8. Dong‐Xue Li · 3 shared papers, 2025 · strength 0.62
  9. Minwei Yang · 4 shared papers, 2021–2026 · strength 0.61
  10. Yan‐Miao Huo · 3 shared papers, 2021–2026 · strength 0.51
  11. Hong‐Fei Yao · 2 shared papers, 2025–2026 · strength 0.41
  12. Yongwei Sun · 3 shared papers, 2021–2024 · strength 0.39
  13. Jia-Hao Zheng · 2 shared papers, 2023–2024 · strength 0.35
  14. Kaixia Zhou · 3 shared papers, 2021 · strength 0.32
  15. Hui Nie · 2 shared papers, 2022–2025 · strength 0.32
  16. Qing Li · 3 shared papers, 2021–2022 · strength 0.32
  17. Jian‐Yu Yang · 2 shared papers, 2021–2023 · strength 0.28
  18. Wei Liu · 1 shared paper, 2026 · strength 0.24
  19. Zheng Wu · 1 shared paper, 2025 · strength 0.21
  20. Shan Zhang · 1 shared paper, 2025 · strength 0.21
  21. Qing Ye · 1 shared paper, 2025 · strength 0.21
  22. Aziguli Tulamaiti · 1 shared paper, 2025 · strength 0.21
  23. Xia-Qing Li · 1 shared paper, 2025 · strength 0.21
  24. Xu Wang · 2 shared papers, 2021 · strength 0.20
  25. Dejun Liu · 2 shared papers, 2021 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.